Post-orgasmic illness syndrome accompanied with testosterone deficiency: a case report

Post-orgasmic illness syndrome (POIS) is a rare disease that affects the quality of life of patients. Here, we report a case of a 27-year-old man who visited our clinic and presented with physical fatigue, muscle weakness, emotional irritability, memory difficulties, lack of attention, and flu-like state after ejaculation. The patient was diagnosed with POIS accompanied by testosterone deficiency (TD) and treated with antiallergic therapy combined with testosterone supplementation therapy (TST) and selective serotonin reuptake inhibitor (SSRI). After 3 months of medication, the patient’s POIS symptoms, testosterone levels, and relevant questionnaire scores significantly improved. Antiallergic therapy combined with TST and SSRI treatment can effectively treat patients with POIS accompanied by TD.

Post-orgasmic illness syndrome; Antiallergic therapy; Testosterone deficiency; Testosterone supplementation therapy

[1] Waldinger MD, Meinardi MM, Zwinderman AH, Schweitzer DH. Postorgasmic Illness Syndrome (POIS) in 45 Dutch Cau-casian Males: Clinical Characteristics and Evidence for an Immunogenic Pathogenesis (Part 1). The Journal of Sexual Medicine. 2011; 8: 1164–1170.

[2] Abdessater M, Elias S, Mikhael E, Alhammadi A, Beley S. Post orgasmic illness syndrome: what do we know till now? Basic Clinical Andrology. 2019; 29: 13.

[3] Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49: 822–830.

[4] Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. De-velopment and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International Journal of Impotence Research. 1999; 11: 319–326.

[5] Nguyen HMT, Bala A, Gabrielson AT, Hellstrom WJG. Post-Orgasmic Illness Syndrome: A Review. Sexual Medicine Re-views. 2018; 6: 11–15.

[6] Waldinger MD, Schweitzer DH. Postorgasmic illness syndrome: two cases. Journal of Sex and Marital Therapy. 2002; 28: 251–255.

[7] Jiang N, Xi G, Li H, Yin J. Postorgasmic illness syndrome (POIS) in a Chinese man: no proof for IgE-mediated allergy to semen. The Journal of Sexual Medicine. 2015; 12: 840–845.

[8] Depreux N, Basagaña M, Pascal M. Negative allergy study in a case of postorgasmic illness syndrome (POIS). Revista Interna-cional De Andrologia. 2018; 16: 42–44.

[9] De Amicis K, Costa PR, Figo DD, De Lima CMF, Castro FFM, Kalil J, et al. Immunophenotypical Characterization of a Brazil-ian POIS (Post-Orgasmic Illness Syndrome) Patient: Adding more Pieces to Puzzle. Journal of Sex & Marital Therapy. 2020; 46: 227–233.

[10] Waldinger MD, Meinardi MM, Schweitzer DH. Hyposensiti-zation therapy with autologous semen in two Dutch caucasian males: beneficial effects in Postorgasmic Illness Syndrome (POIS; Part 2). The Journal of Sexual Medicine. 2011; 8: 1171–1176.

[11] Ashby J, Goldmeier D. Postorgasm illness syndrome–a spec-trum of illnesses. The Journal of Sexual Medicine. 2010; 7: 1976–1981.

[12] Reisman Y. Clinical experience with post-orgasmic illness syn-drome (POIS) patients-characteristics and possible treatment modality. International Journal of Impotence Research. 2021; 33: 556–562.

[13] Kim TB, Shim YS, Lee SM, Son ES, Shim JW, Lee SP. Intra-lymphatic Immunotherapy with Autologous Semen in a Korean Man with Post-Orgasmic Illness Syndrome. Sexual Medicine. 2018; 6: 174–179.

[14] Althof SE, McMahon CG. Contemporary Management of Disor-ders of Male Orgasm and Ejaculation. Urology. 2016; 93: 9–21.

[15] Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: a Review and Comparison of Current Guidelines. The Journal of Sexual Medicine. 2019; 16: 812–820.

[16] Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of an-drogens on the immune system. Cellular Immunology. 2015; 294: 87–94.

[17] Bolanos J, Morgentaler A. Successful treatment of Post-orgasmic illness syndrome with human chorionic gonadotropin. Urology Case Reports. 2020; 29: 101078.

[18] MacQueen G, Born L, Steiner M. The selective serotonin reup-take inhibitor sertraline: its profile and use in psychiatric disor-ders. CNS Drug Reviews. 2001; 7: 1–24.

[19] Jing E, Straw-Wilson K. Sexual dysfunction in selective sero-tonin reuptake inhibitors (SSRIs) and potential solutions: a nar-rative literature review. Mental Health Clinician. 2016; 6: 191–196.